ISMRM 24th Annual Meeting & Exhibition • 07-13 May 2016 • Singapore |
|
Educational Session: ISMRM/SMRT Joint Forum: Update on MRI Contrast Agents: Recent Controversies
Skill Level: Beginner
Organizers: Chris Kokkinos, B.App.Sc., Pg.Cert.(MRI) & Scott B. Reeder, M.D., Ph.D.
Monday 09 May 2016
|
Overview
The number and variety of available MR-based contrast agents continues to evolve. In this session, recent controversies surrounding the use and safety of gadolinium and iron based contrast agents will be discussed in an interactive session, aimed at generating discussion and interaction among experts in the field.
Target Audience
This course is designed for:
- Physicians including cardiologists and neurologists, Radiologists, MRI Technologists, MR Engineers or Physicists, Bioengineers and all fields related to these disciplines;
- Medical, Biological and Industrial Researchers with an interest in MRI Contrast Agents;
- Experienced researchers seeking to learn about MRI Contrast Agents, and is actively engaged in research in this or related fields; and
- Undergraduate, graduate students, and technologists are highly encouraged to participate.
Educational Objectives
Upon completion of this course, participants should be able to:
- Assess recent safety data on nephrogenic systemic fibrosis (NSF) and the emerging role of screening to avoid NSF;
- Interpret recently reported data on deposition of gadolinium in the brain; and
- Evaluate emerging applications and recent safety considerations regarding the use of ferumoxytol as an MRI contrast agent.
|
|
PROGRAM |
|
Moderators: Jeffrey C. Weinreb |
14:15
|
Update on Nephrogenic Systemic Fibrosis: Should We Stop
Screening? - Permission Withheld
Sadhana Nandwana
This presentation will provide a current update on
nephrogenic systemic fibrosis (NSF) and where we stand
with exposure of selected gadolinium based contrast
agents (GBCAs) in renally impaired patients and risk of
NSF. Risk stratification based on safety profiles of
GBCAs and current national and international guidelines
and recommendations will be examined. Evaluation of
whether these guidelines should be modified in light of
recent publications demonstrating a lack of NSF
occurrence in patients exposed to specific GBCAs will be
discussed.
|
14:45
|
Panel Discussion |
14:55
|
Gadolinium Deposition: Imaging Phenomenon or Should We
Change Our Practice? 
Greg C. Brown1
1Centre for Advanced Imaging, The University
of Queensland, St Lucia, Australia
Reports of gadolinium accumulation in the brain have
surprised many practitioners, and raised questions of
potential harm to patients. The FDA & NIH recommend
reconsideration of GBCA use while investigations
continues. The accumulation calls into doubt a common
assumption that existing renal function mediated
guidelines are sufficient to avoid significant
biological interaction. This presentation reviews the
recent reports and presents literature concerning
gadolinium chelate stability, transmetalation,
gadolinium interactions in biochemistry, observations of
bone and skin accumulation (beyond NSF definitions), and
environmental build up to provide a context for a
reconsideration by clinical and research practitioners
of our current GBCA usage.
|
15:25
|
Panel Discussion |
15:35
|
Ferumoxytol: Should We Be Using It in Clinical Practice?
Mustafa Bashir1
1Duke University Medical Center
Ferumoxytol has seen increasing use as a contrast agent
in both clinical and research MRI. This talk will
describe some of the potential uses and risks associated
with the agent.
|
16:05
|
Panel Discussion |
16:15
|
Adjournment & Meet the
Teachers |
|
| |
|
|
|
|
| |
|
The International Society for Magnetic Resonance in Medicine is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians. |